About six months after the FDA approved the first treatment for peanut allergy, a new biotech, IgGenix, has raised $10 million to discover antibodies that could address that and other common... Read more »
A skin patch developed by DBV Technologies to desensitize peanut allergy sufferers to the allergen over time has been rejected by the FDA, which says the French company needs to change... Read more »
CymaBay Therapeutics’ investigational drug seladelpar succeeded in a late-stage trial in patients with primary biliary cholangitis (PBC), producing results that suggest it could have a key side effect advantage compared to... Read more »
Another biopharma has signed up to use Sangamo Therapeutics’ gene editing technology to develop therapies that can address disease by heightening or depressing a gene’s activity level.
Sangamo on Thursday announced... Read more »
Public investors are betting big on biotechs, and Inhibrx is looking to capitalize on the industry’s recent resurgence of initial public offerings.
The La Jolla, CA-based company, which is developing drugs... Read more »
Damage to axons, the slender tendrils through which nerve cells communicate, is an early indication of several neurological diseases. Nura Bio, which formed around new research into a mechanism underlying axonal... Read more »
Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and... Read more »
Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors.
The San Diego-based telehealth company’s software links primary... Read more »
EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices... Read more »
[Corrected 7/23/20, 10:13 am. See below.] Jazz Pharmaceuticals has received FDA approval for a narcolepsy drug that it has developed as a lower-sodium successor to its biggest moneymaker, a treatment... Read more »
Illumina led the genomics revolution, developing tools that have changed how scientists discover drugs and how clinicians treat patients. Startup Seer is making the case that its technology for analyzing the... Read more »
Olema Oncology has raised $54 million to advance its lead drug candidate into human tests, having been working in stealth since 2007 to develop a daily pill to treat women with breast cancer... Read more »
Elevation Oncology formed last year with $32.5 million in a Series A financing round led by the initial investor in Loxo Oncology, a company that blazed a trail developing cancer therapies... Read more »
Gilead Sciences has made its second deal in as many months that puts the company first in line to acquire a biotech developing cancer immunotherapies.
On Tuesday the Foster City, CA-based... Read more »
Acadia Pharmaceuticals received the FDA’s OK for pimavanserin (Nuplazid), the first drug approved to treat hallucinations and delusions associated with Parkinson’s disease, in 2016. Since then, the San Diego company... Read more »
Venture capitalists like nothing more than pattern matching, and Domain Associates has identified one it especially prefers: licensing drug candidates from a Japanese biopharma and setting up a US company to... Read more »
A gene therapy being jointly developed by MeiraGTx and Johnson & Johnson to treat an inherited disease of the retina that leads to blindness improved patients’ vision after six months, data... Read more »
There’s a hard and fast rule at Adimab, a company that makes money by discovering and optimizing antibodies to pass off to drug development companies: Don’t compete with the customers.
So,... Read more »
Dewpoint Therapeutics has signed its second biopharma partnership, teaming up with Merck to explore the potential of using its discoveries around “droplets” of biomolecules that form inside cells to create a... Read more »
The drug that Equillium licensed from India-based pharma giant Biocon has received authorization for emergency use in that country in patients hospitalized with COVID-19.
The treatment, itolizumab, reduced mortality in a... Read more »